Total Funding
52
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
207185
CMT focuses on the development and commercialization of regenerative therapies derived from novel processed human platelets.
Acquired by 
Cambium Bio (formally Regeneus)
Edmund Waller: Founding Partner
Terence Walts: President & CEO
About the Company
Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop for
dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.
